Author/Authors :
Miyoshi، Yasuhide نويسنده Department of Urology, Yokohama City Medical Center, Yokohama, Japan , , Furuya، Masahiro نويسنده Department of Urology, Yokohama City Medical Center, Yokohama, Japan , , Teranishi، Jun ichi نويسنده Department of Urology, Yokohama City Medical Center, Yokohama, Japan , , Noguchi، Kazumi نويسنده Department of Urology, Yokohama City University, Medical Center, Yokohama, Japan. , , Uemura، Hiroji نويسنده Department of Urology, Yokohama City Medical Center, Yokohama, Japan , , Yokomizo، Yumiko نويسنده Department of Urology, Yokohama City Medical Center, Yokohama, Japan , , Sugiura، Shinpei نويسنده Department of Urology, Yokohama City Medical Center, Yokohama, Japan , , Kubota، Yoshinobu نويسنده ,
Abstract :
Purpose: In the present study, we compared 12- with 16-core biopsy in patients with prostate-
specific antigen (PSA) levels of 4.0-20.0 ng/mL.
Materials and Methods: Between 2003 and 2010, 332 patients whose serum PSA level was
between 4.0 and 20.0 ng/mL underwent initial transrectal ultrasound (TRUS)-guided needle
biopsy. Of those patients, 195 underwent 12-core biopsy and 137 underwent 16-core biopsy.
Results: In the 12-core prostate biopsy group, 66 (33.8%) patients were found to have prostate
cancer. On the other hand, in the 16-core prostate biopsy group of 137 patients, 61 (44.5%)
were found to have prostate cancer. Among all patients, the prostate cancer detection rate
was slightly higher in the 16-core biopsy group than in the 12-core biopsy group. Moreover,
in patients with prostate volume > 30 mL or PSA density (PSAD) < 0.2, the prostate cancer
detection rate was significantly higher in the 16-core biopsy group than in the 12-core biopsy
group. There was no significant difference in pathological tumor grade, indolent cancer probability,
or biopsy complication rate between the two groups.
Conclusion: In order to detect prostate cancer, 16-core prostate biopsy is safe and feasible
for Japanese patients with serum PSA level of 4.0-20.0 ng/mL.
